Humberto Álvarez López
Research Subjects
Humberto Álvarez López has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Ernesto German Cardona-Muñoz
Department of Physiology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico
3 shared publications - Adolfo Chávez-Mendoza
Grupo de Expertos en Hipertensión Arterial México (GREHTA) Ciudad de México Mexico
2 shared publications - Héctor Galván-Oseguera
Grupo de Expertos en Hipertensión Arterial México (GREHTA) Ciudad de México Mexico
2 shared publications - Luis Alcocer
Mexican Institute of Cardiovascular Health, Mexico City, Mexico
2 shared publications - Luis Rey García-Cortés
Coordinación de Investigación del Estado de México Oriente, Insitituto Mexicano del Seguro Social, Tlalnepantla de Baz 50090, Mexico
2 shared publications - Martin Rosas-Peralta
Grupo de Expertos en Hipertensión Arterial México (GREHTA) Ciudad de México Mexico
2 shared publications
Latest Publications
- Open Access
- 2 August 2025
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 27 (8) , e70106
Comparison of Globorisk, SCORE2, and PREVENT in the Stratification of Cardiovascular Risk and its Relationship with End‐Organ Damage Among Adults With Arterial Hypertension
Arterial hypertension often coexists with comorbidities that increase vascular damage. Although the primary goal is to reduce cardiovascular risk, the available risk scores can produce varying estimates. Here, we aim to compare the prevalence of cardiovascular risk categories using three equations (Globorisk, SCORE2, and PREVENT) in adults living with arterial hypertension and to assess their association as stratification tools for end‐organ damage (EOD). To achieve this, we performed a cross‐sectional sub‐analysis of the RIHTA study, an electronic health record‐based registry of adults with arterial hypertension in Mexican primary care centers. EOD was defined as aortic stiffness, reduced eGFR, hypertensive retinopathy, peripheral artery disease, or left ventricular hypertrophy. Inverse probability weighting (IPW) was used to evaluate the association between cardiovascular risk and EOD, adjusting for relevant confounders, and areas under the receiver operator curve (AUROC) were calculated to assess detection capacity. Among 4512 participants (median age 64 years; 61% women), EOD was present in 33% (n = 1492). The PREVENT equation yielded the highest median 10‐year risk (15%, IQR 8–24), followed by Globorisk laboratory‐based (12%, 7–22), Globorisk office‐based (11%, 7–19), and SCORE2 (5.06%, 3.86–7.18). In IPW models, each 1% increase in score was associated with higher odds of EOD (PREVENT OR 1.16, 95% CI 1.15–1.17; Globorisk‐office 1.09, 1.08–1.10; Globorisk‐lab 1.07, 1.06–1.08; SCORE2 1.04, 1.02–1.06). The PREVENT score demonstrated the strongest discrimination for detecting EOD (AUROC: 0.751, 0.735–0.750). These findings suggest that among adults with arterial hypertension, the PREVENT score identifies high‐risk individuals and improves discrimination for EOD.
- 2 August 2025
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 27 (8) , e70106
Open AccessComparison of Globorisk, SCORE2, and PREVENT in the Stratification of Cardiovascular Risk and its Relationship with End‐Organ Damage Among Adults With Arterial Hypertension
Arterial hypertension often coexists with comorbidities that increase vascular damage. Although the primary goal is to reduce cardiovascular risk, the available risk scores can produce varying estimates. Here, we aim to compare the prevalence of cardiovascular risk categories using three equations (Globorisk, SCORE2, and PREVENT) in adults living with arterial hypertension and to assess their association as stratification tools for end‐organ damage (EOD). To achieve this, we performed a cross‐sectional sub‐analysis of the RIHTA study, an electronic health record‐based registry of adults with arterial hypertension in Mexican primary care centers. EOD was defined as aortic stiffness, reduced eGFR, hypertensive retinopathy, peripheral artery disease, or left ventricular hypertrophy. Inverse probability weighting (IPW) was used to evaluate the association between cardiovascular risk and EOD, adjusting for relevant confounders, and areas under the receiver operator curve (AUROC) were calculated to assess detection capacity. Among 4512 participants (median age 64 years; 61% women), EOD was present in 33% (n = 1492). The PREVENT equation yielded the highest median 10‐year risk (15%, IQR 8–24), followed by Globorisk laboratory‐based (12%, 7–22), Globorisk office‐based (11%, 7–19), and SCORE2 (5.06%, 3.86–7.18). In IPW models, each 1% increase in score was associated with higher odds of EOD (PREVENT OR 1.16, 95% CI 1.15–1.17; Globorisk‐office 1.09, 1.08–1.10; Globorisk‐lab 1.07, 1.06–1.08; SCORE2 1.04, 1.02–1.06). The PREVENT score demonstrated the strongest discrimination for detecting EOD (AUROC: 0.751, 0.735–0.750). These findings suggest that among adults with arterial hypertension, the PREVENT score identifies high‐risk individuals and improves discrimination for EOD.
- Open Access
- 11 March 2024
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 37 (7) , 503-513
Patients Living With Arterial Hypertension in Mexico: First Insights of The Mexican Registry of Arterial Hypertension (RIHTA Study)
Arterial hypertension is a significant cause of morbidity and mortality in Mexico. However, there is limited evidence to understand blood pressure management and cardiometabolic profiles. Here, we aim to assess the prevalence of controlled and uncontrolled blood pressure, as well as the prevalence of cardiometabolic risk factors among patients from the Mexican Registry of Arterial Hypertension (RIHTA). We conducted a cross-sectional analysis of participants living with arterial hypertension registered on RIHTA between December 2021 and April 2023. We used both the 2017 ACC/AHA and 2018 ESC/ESH thresholds to define controlled and uncontrolled arterial hypertension. We considered eleven cardiometabolic risk factors, which include overweight, obesity, central obesity, insulin resistance, diabetes, hypercholesterolemia, hypertriglyceridemia, low HDL-C, high LDL-C, low-eGFR, and high cardiovascular disease (CVD) risk. In a sample of 5,590 participants (female: 61%, n = 3,393; median age: 64 [IQR: 56–72] years), the prevalence of uncontrolled hypertension varied significantly, depending on the definition (2017 ACC/AHA: 59.9%, 95% CI: 58.6–61.2 and 2018 ESC/ESH: 20.1%, 95% CI: 19.0–21.2). In the sample, 40.43% exhibited at least 5–6 risk factors, and 32.4% had 3–4 risk factors, chiefly abdominal obesity (83.4%, 95% CI: 82.4–84.4), high LDL-C (59.6%, 95% CI: 58.3–60.9), high CVD risk (57.9%, 95% CI: 56.6–59.2), high triglycerides (56.2%, 95% CI: 54.9–57.5), and low HDL-C (42.2%, 95% CI: 40.9–43.5). There is a high prevalence of uncontrolled hypertension interlinked with a high burden of cardiometabolic comorbidities in Mexican adults living with arterial hypertension, underscoring the urgent need for targeted interventions and better healthcare policies to reduce the burden of the disease in our country.
- 11 March 2024
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 37 (7) , 503-513
Open AccessPatients Living With Arterial Hypertension in Mexico: First Insights of The Mexican Registry of Arterial Hypertension (RIHTA Study)
Arterial hypertension is a significant cause of morbidity and mortality in Mexico. However, there is limited evidence to understand blood pressure management and cardiometabolic profiles. Here, we aim to assess the prevalence of controlled and uncontrolled blood pressure, as well as the prevalence of cardiometabolic risk factors among patients from the Mexican Registry of Arterial Hypertension (RIHTA). We conducted a cross-sectional analysis of participants living with arterial hypertension registered on RIHTA between December 2021 and April 2023. We used both the 2017 ACC/AHA and 2018 ESC/ESH thresholds to define controlled and uncontrolled arterial hypertension. We considered eleven cardiometabolic risk factors, which include overweight, obesity, central obesity, insulin resistance, diabetes, hypercholesterolemia, hypertriglyceridemia, low HDL-C, high LDL-C, low-eGFR, and high cardiovascular disease (CVD) risk. In a sample of 5,590 participants (female: 61%, n = 3,393; median age: 64 [IQR: 56–72] years), the prevalence of uncontrolled hypertension varied significantly, depending on the definition (2017 ACC/AHA: 59.9%, 95% CI: 58.6–61.2 and 2018 ESC/ESH: 20.1%, 95% CI: 19.0–21.2). In the sample, 40.43% exhibited at least 5–6 risk factors, and 32.4% had 3–4 risk factors, chiefly abdominal obesity (83.4%, 95% CI: 82.4–84.4), high LDL-C (59.6%, 95% CI: 58.3–60.9), high CVD risk (57.9%, 95% CI: 56.6–59.2), high triglycerides (56.2%, 95% CI: 54.9–57.5), and low HDL-C (42.2%, 95% CI: 40.9–43.5). There is a high prevalence of uncontrolled hypertension interlinked with a high burden of cardiometabolic comorbidities in Mexican adults living with arterial hypertension, underscoring the urgent need for targeted interventions and better healthcare policies to reduce the burden of the disease in our country.
- 1 February 2021
- Published by Elsevier in Archives of Medical Research
- Vol. 52 (2) , 233-239
Obesity Paradox and 12 Month Outcome in Patients with Atrial Fibrillation
- 1 February 2021
- Published by Elsevier in Archives of Medical Research
- Vol. 52 (2) , 233-239
Obesity Paradox and 12 Month Outcome in Patients with Atrial Fibrillation